

# Investigating the Impact of Gut Microbiota on Gout Through Mendelian Randomization

Chaoqun Tang<sup>1</sup>, Lei Li<sup>2</sup>, Xin Jin<sup>2</sup>, Jinfeng Wang<sup>2</sup>, Debao Zou<sup>2</sup>, Yan Hou<sup>2</sup>, Xin Yu<sup>2</sup>, Zhizhou Wang<sup>2</sup>, Hongjiang Jiang<sup>1,2</sup>

<sup>1</sup>The First Clinical Medical School, Anhui University of Chinese Medicine, Hefei, Anhui, People's Republic of China; <sup>2</sup>Department of Orthopedics, Shandong Wendeng Osteopathic Hospital, Wendeng, Weihai, Shandong, People's Republic of China

Correspondence: Hongjiang Jiang, Department of Orthopedics, Shandong Wendeng Osteopathic Hospital, Wendeng, Weihai, Shandong, People's Republic of China, Tel +86-19819687688, Email boneman@163.com

**Background:** The relationship between gout and gut microbiota has attracted significant attention in current research. However, due to the diverse range of gut microbiota, the specific causal effect on gout remains unclear. This study utilizes Mendelian randomization (MR) to investigate the causal relationship between gut microbiota and gout, aiming to elucidate the underlying mechanism of microbiome-mediated gout and provide valuable guidance for clinical prevention and treatment.

**Materials and Methods:** The largest genome-wide association study meta-analysis conducted by the MiBioGen Consortium (n=18,340) was utilized to perform a two-sample Mendelian randomization investigation on aggregate statistics of intestinal microbiota. Summary statistics for gout were utilized from the data released by EBI. Various methods, including inverse variance weighted, weighted median, weighted model, MR-Egger, and Simple-mode, were employed to assess the causal relationship between gut microbiota and gout. Reverse Mendelian randomization analysis revealed a causal association between bacteria and gout in forward Mendelian randomization analysis. Cochran's Q statistic was used to quantify instrumental variable heterogeneity.

**Results:** The inverse variance weighted estimation revealed that *Rikenellaceae* exhibited a slight protective effect on gout, while the presence of *Ruminococcaceae UCG\_011* is associated with a marginal increase in the risk of gout. According to the reverse Mendelian Randomization results, no significant causal relationship between gout and gut microbiota was observed. No significant heterogeneity of instrumental variables or level pleiotropy was detected.

**Conclusion:** Our MR analysis revealed a potential causal relationship between the development of gout and specific gut microbiota; however, the causal effect was not robust, and further research is warranted to elucidate its underlying mechanism in gout development. Considering the significant association between diet, gut microbiota, and gout, these findings undoubtedly shed light on the mechanisms of microbiota-mediated gout and provide new insights for translational research on managing and standardizing treatment for this condition.

**Keywords:** Gout, Gut Microbiota, Mendelian Randomization, Diet

## Introduction

Gout, a chronic disease characterized by the deposition of monosodium urate crystals, affects 41 million individuals globally with an incidence rate ranging from 0.58 to 2.89 per 1000 person-years,<sup>1-3</sup> placing a burden on individual health and healthcare systems. The condition can lead to painful inflammatory arthritis and other comorbidities, and is strongly associated with obesity, hyperlipidemia, type 2 diabetes, and other conditions. Additionally, it serves as an independent predictor of premature death.<sup>4,5</sup> In the pathogenesis of this disease, the deposition of urate salts promotes synovial inflammation (synovitis), leading to arthritis,<sup>6</sup> while elevated serum uric acid levels (hyperuricemia) play a crucial role in facilitating monosodium urate (MSU) crystal deposition and driving pain progression.<sup>7</sup> Therefore, it is imperative to lower uric acid levels in order to effectively prevent gout attacks.<sup>8</sup> In clinical practice, the hallmark of this disease is the abrupt onset of joint inflammation. Henceforth, the pivotal role lies in the natural immune pathway, particularly in the activation of NLRP3 inflammasome, which triggers the release of IL-1 $\beta$  and other pro-inflammatory cytokines.<sup>9</sup> Studies

have demonstrated that long-chain fatty acids (C18) may contribute to the release of IL-1 $\beta$  during macrophage phagocytosis of MSU crystals.<sup>10</sup> Moreover, clinical evidence indicates a negative correlation between the dietary intake of omega-3 fatty acids and the incidence of acute gout attacks.<sup>11</sup> The aforementioned studies collectively suggest that dietary intake may be a contributing factor in the pathogenesis of gout inflammation.

The role of diet as a risk factor for gout has been well-documented, and dietary factors can significantly influence urate production.<sup>1</sup> Considering the pivotal role of gut microbiota in mediating the extensive impact of diet on human health and disease, it is plausible to hypothesize that alterations in the composition of gut microbiota may also exert an influence on the pathogenesis of gout.<sup>12</sup> The gut microbiota plays a pivotal role in the process of food digestion and exerts a significant influence on the overall metabolism of the human body.<sup>13</sup> Gut microbiota can also affect serum uric acid levels. Studies have shown that the Dietary Approaches to Stop Hypertension (DASH) diet can significantly reduce serum uric acid levels in patients with hyperuricemia.<sup>14</sup> Furthermore, studies investigating the impact of high-fiber diets on gout have suggested that these diets may exert an anti-inflammatory effect by augmenting acetate and other short-chain fatty acid production, thereby influencing neutrophil activity.<sup>15</sup> The findings suggest that dysbiosis of the gut microbiota, characterized by a decrease in microbial diversity and alterations in specific bacterial taxa, may be associated with an elevated risk of gout. The aforementioned studies provide valuable insights into the potential role of gut microbiota in the pathogenesis of gout. Further investigations are warranted to gain a more comprehensive understanding of the underlying mechanisms and to pinpoint potential therapeutic targets for the prevention and treatment of this prevalent ailment.

Gut microbiota and its metabolites have been observed to be implicated in the pathogenesis of metabolic diseases,<sup>16,17</sup> playing key roles in key biological processes such as metabolic interactions and host immune responses, such as polyamines, short-chain fatty acids (SCFAs), and aryl hydrocarbon receptor (AHR) ligands. It may affect the immune response and disease progression by interacting with host intestinal cells.<sup>18</sup> The pathogenesis of gout involves an inflammatory rheumatic condition characterized by arthritis and perturbed uric acid metabolism, which is widely acknowledged in the scientific community.<sup>19</sup> The intestinal tract serves as the principal pathway for uric acid excretion. Studies have demonstrated a reduction in both richness and diversity of gut microbiota among individuals with gout,<sup>20</sup> including a decrease in  $\alpha$  diversity.<sup>21</sup> *Lactic acid bacteria* and *Pseudomonas* facilitate the excretion of uric acid in the intestines through the production of short-chain fatty acids.<sup>22</sup> The intestinal flora of hyperuricemic rats exhibits a decreased abundance of *Lactic acid bacteria*, *Streptococcus*, and *Clostridium*, which are involved in purine absorption and uric acid breakdown. Conversely, there is an increased abundance of *Proteus*, known for its secretion of xanthine dehydrogenase.<sup>23</sup> Although these studies have confirmed the dysbiosis of gut microbiota in gout patients, the causal relationship between gut microbiota dysbiosis and the development of gout remains unclear. Therefore, further investigation is necessary to elucidate the causal association between gout and gut microbiota.

In observational studies, the association between gut microbiota and gout is influenced by confounding factors such as age, environmental conditions, dietary patterns, and lifestyle choices.<sup>24–26</sup> Reaching effective control over these factors in observational studies thus presents a significant challenge. These conditions impose limitations on establishing causal relationships between gut microbiota and gout. Mendelian randomization (MR) represents a novel approach to investigate the causal association between gut microbiota and gout. The principle of MR can be employed to assess the causal relationship between exposure factors (such as gut bacteria) and outcomes (like gout) by leveraging genetic markers associated with the exposure, while satisfying specific assumptions.<sup>27</sup> Furthermore, the MR has been extensively employed to investigate the causal association between microbiota and diseases, such as rheumatoid arthritis.<sup>28</sup> However, two-sample MR employs single nucleotide polymorphism (SNP) data and independent genome-wide association study (GWAS) results to establish correlations and integrate them into a unified estimate of causality.<sup>29</sup> The present study employed a double-sample MR technique, utilizing aggregated statistics derived from MiBioGen's GWAS, to investigate the causal association between gut microbiota and gout.

## Material and Methods

### Overview of Research

The analysis employed a two-sample Mendelian randomization approach, treating each of the 196 gut microbiota species (Table S1) as an individual exposure factor while considering gout as the outcome. The assumptions for MR studies

necessitate the following: 1) a strong correlation between instrumental variables and exposure factors; 2) no correlation between instrumental variables and confounders; 3) the absence of direct association between the instrumental variable and the outcome, with its impact on the outcome solely reflected through exposure.

## Data Sources

The gout data utilized in this study was derived from the comprehensive dataset compiled by the EBI database in 2021 (N=166,401). The intestinal flora data comes from the international alliance MiBioGen (N=18,340), which collected the data of 24S rRNA gene sequencing map and genotyping for 18,340 participants from 16 cohorts in the United States, Canada, Israel, Korea, Germany, Denmark, the Netherlands, Belgium, Sweden, Finland and the United Kingdom.<sup>30</sup>

## Selection of Instrumental Variables

The initial screening of intestinal flora identified a total of 211 taxa, out of which 196 taxa were included in the experimental criteria after excluding 15 unknown taxa. These encompassed 9 phyla, 16 classes, 20 orders, 32 families, and 119 genera.

The SNPs of the 196 bacterial taxa were selected based on the following criteria: 1) Due to insufficient SNPs obtained from  $p < 5 \times 10^{-8}$  screening, this criterion was revised and a threshold of  $p < 1 \times 10^{-5}$  was used instead. 2) The LD criteria for selecting conforming SNPs from point 1) were as follows:  $r^2 = 0.001$ , kb = 10,000 to ensure independence of the obtained SNPs. 3) The F-statistic of each SNP was calculated, and instrumental variables with  $F > 10$  were chosen to mitigate weak instrumental bias.<sup>31</sup> Detailed data are available at [Table S2](#) and [Table S3](#).

## Mendelian Randomization Studies and Sensitivity Analysis

In this study, the inverse variance weighted method (IVW) was employed to investigate the causal effect of intestinal flora on gout. To enhance the stability and reliability of experimental findings, four additional methods were utilized: weighted median method, weighted model method, MR-Egger method, and Simple-mod method. The IVW method, known for its high reliability, was chosen as the gold standard in cases where the causal effect varied across the five outcomes.

The Cochran's Q statistic was computed to quantify and assess the potential heterogeneity ([Table S4](#)), while the MR-Egger intercept test was employed to estimate pleiotropy levels. To ensure result reliability, a leave-one-out approach was utilized to examine the impact of each SNP on overall results and evaluate its heterogeneity.

Meanwhile, to mitigate errors arising from confounding factors in the experiment, we employed PhenoScanner (<http://www.phenoscaner.medschl.cam.ac.uk>) for querying instrumental variable SNPs during experimental selection. The objective was to ensure that all SNPs satisfied the three fundamental assumptions of the Mendelian randomization study<sup>2) 3) article</sup>.

## Statistical Analysis

Considering the inclusion of n bacterial flora at various taxonomic levels, including phylum, class, family, order, species and genus, the significance threshold was adjusted using Bonferroni correction.<sup>32</sup> The p-values for the door, class, division, mesh, species and genus are calculated using the formula  $0.05 / n$  as follows:  $5.56 \times 10^{-3}$ ,  $3.13 \times 10^{-3}$ ,  $2.5 \times 10^{-3}$ ,  $1.56 \times 10^{-3}$  and  $4.20 \times 10^{-4}$ . In the experimental results, we observed a significant p-value below 0.05 after applying Bonferroni correction, indicating statistical significance. However, it should be noted that even though the p value was less than 0.05 but did not meet the criteria for Bonferroni correction, it was still considered to have potential statistical significance.

The experiments were primarily conducted using the Two-Sample-MR package (version 0.5.7) within the R software environment (version 4.3.1).

## Results

### Description of Instrumental Variables

The screening process involved the application of genome-wide significance thresholds ( $p < 1 \times 10^{-5}$ ), followed by LD tests to eliminate linkage disequilibrium, data coordination and harmonization, MR-PRESSO tests, and calculation of

F-values. Only SNPs with F-statistic values exceeding 10 were retained to ensure a strong correlation with the corresponding flora.

## Causal Impact of Gut Microbiota on Gout

Inverse variance weighted estimates revealed a potential protective effect of *Rikenellaceae* against gout (OR= 0.9979, 95% CI: 0.9958–1.0000, P-value=  $4.91 \times 10^{-2}$ ). Conversely, *Ruminococcaceae UCG\_011* (OR= 1.0016, 95% CI: 1.0001–1.0031, P-value=  $4.03 \times 10^{-2}$ ) was identified as a risk factor for gout. From Figure 1, it is evident that among the five tests conducted on *Rikenellaceae*, only the IVW method exhibits statistical significance with an OR value approaching unity. Although it demonstrates a certain degree of protective effect, the specific mechanism remains unknown. Similarly, *Ruminococcaceae UCG\_011* displays a positive association with gout; however, the risk effect appears to be relatively weak.

## Sensitivity Analysis

The sensitivity analysis of *Rikenellaceae* bacteria is depicted in Figure 2, while the corresponding analysis for *Ruminococcaceae UCG\_011* bacteria is illustrated in Figure 3.

The Q test revealed no evidence of heterogeneity, and the horizontal pleiotropy test yielded negative results ( $p > 0.05$ ), the data specifics are outlined in Table S4, thereby bolstering the robustness of our findings.

Based on the findings presented in Figure 4, it can be observed that all five estimates of *Rikenellaceae* bacteria exhibit consistent trends, except for MR Egger. Although statistical significance was not achieved, this observation further





Figure 1 Causal impact of gut microbiota on gout.



**Figure 2** The sensitivity analysis of *Rikenellaceae* bacteria.


supports the current conclusion from an additional perspective. Furthermore, all identified causal effects of *Ruminococcaceae UCG\_011* bacteria in Figure 5 demonstrate consistency.

The IVW method, considered as the benchmark in the experimental results of this study, demonstrated statistical significance with a p-value less than 0.05. Although it did not meet the Bonferroni correction for p-values, we still consider the estimated results to be statistically significant. However, out of the 196 bacterial groups included in this study, only two were identified as statistically significant for gout with an odds ratio (OR) value approaching unity. Further research is necessary to validate their specific causal effects.

## Discussion

In this study, we utilized intestinal flora summary statistics from the largest GWAS meta-analysis conducted by the MiBioGen consortium and gout summary statistics from the EBI project open data to perform a two-sample MR analysis aimed at evaluating the causal relationship between intestinal flora and gout. Our findings suggest that *Rikenellaceae* has a protective effect on gout, while *Ruminococcaceae UCG\_011* poses a risk for developing gout. However, due to its OR problem, our exploration of the causal relationship between intestinal flora and gout is still in its exploratory stage. By exploring microbial mechanisms, we indirectly confirmed that our estimated results are more reliable.

Currently, studies have confirmed a reduction in purine metabolism among patients with gout. Based on the study findings, the same group proposed that this reduced purine metabolism, along with an enhanced carbohydrate metabolism of intestinal flora, may lead to uric acid overload.<sup>33</sup> Currently, studies have confirmed a reduction in purine metabolism




**Figure 3** The sensitivity analysis of *Ruminococcaceae UCG\_011* bacteria.

among patients with gout. Based on the study findings, the same group proposed that this reduced purine metabolism, along with an enhanced carbohydrate metabolism of intestinal flora, may lead to uric acid overload,<sup>34</sup> characterized by metabolic hyperuricemia and the deposition of urate crystals in and around the joint.<sup>35</sup> Among these, hyperuricemia resulting from purine metabolism dysfunction serves as a significant risk factor for the development of gouty inflammation.<sup>36</sup> Approximately 70% of uric acid is excreted via the kidney, while the remaining portion is primarily eliminated through feces or undergoes further metabolism by intestinal flora.<sup>37</sup> Guo observed a significant enrichment of xanthine dehydrogenase, a microorganism capable of converting purines into uric acid, in gout patients. Conversely, allantoinase, which facilitates the degradation of uric acid into urea, was notably reduced in these individuals, resulting in the accumulation of uric acid and exacerbation of gout symptoms.<sup>38</sup> Additionally, studies have demonstrated that *Enterobacteriaceae* play a crucial role in uric acid degradation among healthy individuals.<sup>33</sup>

Furthermore, accumulating evidence suggests that the intestinal microbiota not only contributes to purine metabolism and urate excretion but also plays a pivotal role in activating the NLRP3 inflammasome.<sup>39–41</sup> A previous study demonstrated significantly elevated expression levels of NLRP3, ASC, and caspase-1 in both gout and hyperuricemia groups compared to the control group<sup>42</sup>. Additionally, several researchers have reported that NLRP3 can mediate various programmed cell death pathways involved in inflammatory responses, thereby promoting the onset and progression of gout.<sup>43</sup>


Short-chain fatty acids play a crucial role as mediators utilized by intestinal flora to modulate the physiological function and immune response of the host. They possess the ability to sense and suppress inflammatory reactions,



**Figure 4** The five estimates of *Rikenellaceae* bacteria.

including the expression of adhesion molecules and inflammatory mediators, as well as leukocyte chemotaxis.<sup>44</sup> The major short-chain fatty acids involved are acetate, propionate, and butyrate.<sup>45</sup> Recent investigations have demonstrated that propionate can inhibit NLRP3 inflammasome activation by preventing apoptosis-associated speck-like protein (ASC) oligomerization and speck formation. Importantly, this inhibitory effect is independent of G protein-coupled receptor (GPCR) or histone deacetylase (HDAC) signaling pathways.<sup>46</sup> Notably, *Rikenellaceae* has been found to exhibit a negative correlation with proinflammatory cytokines and certain injury factors,<sup>47,48</sup> while also being capable of producing propionate.<sup>49</sup> Given that increased levels of propionate contribute to anti-inflammatory effects,<sup>50</sup> we hypothesize that *Rikenellaceae* may be involved in regulating NLRP3 inflammatory factor metabolism thereby influencing gout-related inflammation.

Furthermore, previous studies have demonstrated a positive correlation between *Rikenellaceae* and the products of amino acid metabolic pathways.<sup>51</sup> It has been established that plasma free amino acids play a crucial physiological role in the biosynthesis and catabolism of various metabolites, as well as acting as modulators for numerous metabolic pathways.<sup>52</sup> Specific amino acids are involved in purine biosynthesis and subsequent uric acid formation. For instance, glutamine, glycine, and serine contribute to increased uric acid production in individuals with gout.<sup>53</sup> Other investigations have indicated that serum glycine and aspartate may participate in purine nucleotide biosynthesis among patients with gout, thereby leading to purine metabolic disorders.<sup>54</sup> Additionally, Mahbub et al observed significantly elevated levels of serum alanine, isoleucine, phenylalanine, leucine, valine, tyrosine, and lysine in individuals with gout.<sup>55</sup> Therefore, it is reasonable to hypothesize that plasma free amino acids play a pivotal role in the pathogenesis of gout.



**Figure 5** The five estimates of *Ruminococcaceae UCG\_011* bacteria.

However, the relationship between *Rikenellaceae* and plasma free amino acids remains unclear, and further extensive research is warranted.

Numerous studies have demonstrated the association of *Rikenellaceae* with protection against cardiovascular and metabolic diseases linked to visceral fat.<sup>56</sup> In a murine model of anthracycline-induced cardiac toxicity, there was a reduced abundance of *Rikenellaceae\_RC9\_gut\_group*.<sup>57</sup> Investigation on obese mice induced by high-fat diet revealed that Sabah polysaccharide could ameliorate obesity through upregulation of *Ricenellaceae\_RC9\_gut\_group*.<sup>58</sup> Given the well-established interrelation between cardiovascular diseases, obesity, and gout,<sup>2,59</sup> these findings collectively support the notion that *Ricenellaceae* exhibits a protective tendency against cardiovascular and metabolic diseases associated with visceral fat, which aligns with our own results.

*Ruminococcaceae* is a gram-positive anaerobe. Molecular studies have demonstrated that the presence of glucan on the cell surface of *R. gnavus* strain ATCC 29149 is dependent on TLR4 receptor binding, indicating its pro-inflammatory properties in vitro by inducing secretion of inflammatory cytokines (TNF- $\alpha$ ).<sup>60</sup> Moreover, an association between increased levels of *R. gnavus* and spondyloarthritis as well as systemic lupus erythematosus has been established.<sup>61,62</sup> In metabolic diseases, Yan found a strong correlation between *R. gnavus* and visceral fat along with positive correlations with metabolic indicators.<sup>63</sup> Additionally, in diabetes research, *R. gnavus* was identified as one of four consistently associated species with disease onset.<sup>64</sup> However, contradicting these findings, Shao observed lower enrichment levels of *Ruminococcaceae UCG\_011* in the intestinal flora of patients with gout.<sup>65</sup> This inconsistency challenges our results; however, considering the overall context of the disease, we believe it still poses a risk effect on gout development due to limited explanatory power provided by SNPs as causal factors. Nonetheless, this does not completely negate the



possibility that *Ruminococcaceae* UCG\_011 may be implicated in increasing risk. In addition, Wang discovered that the genus *Ruminococcaceae* UCG011 is a risk factor for gout.<sup>66</sup> This is consistent with the results of this study and strengthens the credibility of our results.

Due to differences in data, such as the inclusion of different participants, the other researchers have also found that *Escherichia Shigella*, *Lachnospiraceae* NC2004 group, Family XIII AD3011 group, *Coprococcus* 3, *Bifidobacteriales* order and *Bifidobacteriaceae* family are closely related to gout.<sup>67,68</sup> These findings could be mutually complementary with our results.

This study possesses several notable advantages. Firstly, in contrast to previous observational studies investigating the association between gut microbiota and gout, our analysis employed a more refined approach by examining the causal relationship between specific gut microbiota and gout at five taxonomic levels ranging from phylum to genus. Consequently, we identified potential gut microbiota that may exert an impact on gout development. This methodological advancement provides a conceptual framework for elucidating the mechanisms through which particular bacterial strains contribute to gout pathogenesis and offers valuable research insights. For instance, the increased abundance of *Rikenellaceae* and decreased abundance of *Ruminococcus* could potentially be linked to a high-fat diet, suggesting targeted interventions that can mitigate gout incidence associated with such dietary patterns. Secondly, leveraging state-of-the-art large-scale genome-wide association studies (GWAS) enabled us to analyze genetic data from a substantial number of samples, thereby enhancing the credibility of our findings compared to smaller randomized controlled trials. Furthermore, employing MR analysis helped circumvent confounding factors and provided novel perspectives for unraveling the intricate interplay between gut microbiota and gout.

Although this study supports the hypothesis of MR analysis, certain limitations should be acknowledged. The gout and gut microbiota database utilized in this study did not encompass Asian and African populations, thus generalizability to the global population cannot be guaranteed. Further investigations will be conducted to address this issue. Additionally, the stringent screening threshold employed may have excluded some SNPs with a causal relationship with gout. To provide additional theoretical evidence supporting the gut-gout axis mechanism, correlation studies at the species level with a larger sample size are warranted.

## Conclusion

In summary, our study has unveiled the advantageous and precarious gut microbiota associated with gout. When combined with existing research, it becomes evident that the gut microbiota plays a pivotal role in both the development and management of gout, thereby holding significant implications for its clinical prevention and treatment. Moreover, diet-induced systemic metabolic pathways, energy balance, and alterations in gut microbiota also offer novel insights into the mechanisms and potential interventions for comprehending the progression of gout. In conclusion, the implementation of dietary modifications accompanied by effective regulatory mechanisms may represent a viable strategy for mitigating the high prevalence of gout. These findings present new avenues for our subsequent animal experiments to explore the impact of diet on intervention and its potential mechanisms based on gut microbiota.

## Data Sharing Statement

The dataset utilized in this study is available for download from the MiBioGen repository (<https://mibiogen.gcc.rug.nl/>), and EBI repository (<https://www.ebi.ac.uk/>).

## Ethical Statement

According to Article 32 of the Measures for Ethical Review of Life Science and Medical Research Involving Human Beings adopted by the National Science and Technology Ethics Committee of the People's Republic of China, ethical review can be exempted because the data used in this study do not cause any harm to human beings, do not involve any sensitive personal information or commercial interests, and the databases selected are open and legal.

## Acknowledgments

The authors extend their sincere gratitude to the participants and investigators of the EBI study. Furthermore, the authors would like to express their appreciation to the MiBioGen consortium for providing access to the gut microbiota GWAS summary statistics.

## Funding

This research was funded by TCM Science and Technology Project of Shandong Province, grant number 2019-0798.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. *Best Pract Res Clin Rheumatol*. 2021;35(4):101723. doi:10.1016/j.berh.2021.101723
- Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol*. 2020;16(7):380–390. doi:10.1038/s41584-020-0441-1
- Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet*. 2016;388(10055):2039–2052. doi:10.1016/S0140-6736(16)00346-9
- Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. *BMC Med*. 2017;15(1):123. doi:10.1186/s12916-017-0890-9
- Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. *Nat Rev Rheumatol*. 2022;18(2):97–111.
- Eckenstaler R, Benndorf RA. The role of ABCG2 in the pathogenesis of primary hyperuricemia and Gout-An Update. *Int J Mol Sci*. 2021;22(13):6678. doi:10.3390/ijms22136678
- Wu ZD, Yang XK, He YS, et al. Environmental factors and risk of gout. *Environ Res*. 2022;212(Pt C):113377. doi:10.1016/j.envres.2022.113377
- Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. *Lancet*. 2021;397(10287):1843–1855. doi:10.1016/S0140-6736(21)00569-9
- So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. *Nat Rev Rheumatol*. 2017;13(11):639–647. doi:10.1038/nrrheum.2017.155
- Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1 $\beta$  production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. *Arthritis Rheum*. 2010;62(11):3237–3248. doi:10.1002/art.27667
- Abhishek A, Valdes AM, Doherty M. Low omega-3 fatty acid levels associate with frequent gout attacks: a case control study. *Ann Rheum Dis*. 2016;75(4):784–785. doi:10.1136/annrheumdis-2015-208767
- Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. *Science*. 2018;362(6416):776–780. doi:10.1126/science.aau5812
- Yokose C, McCormick N, Rai SK, et al. Effects of low-fat, Mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors: A secondary analysis of the dietary intervention randomized controlled trial (DIRECT). *Diabetes Care*. 2020;43(11):2812–2820. doi:10.2337/dc20-1002
- Juraschek SP, Gelber AC, Choi HK, Appel LJ, Miller ER. Effects of the dietary approaches to stop hypertension (DASH) diet and sodium intake on serum uric acid. *Arthritis Rheum*. 2016;68(12):3002–3009. doi:10.1002/art.39813
- Vieira AT, Galvão I, Macia LM, et al. Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice. *J Leukoc Biol*. 2017;101(1):275–284. doi:10.1189/jlb.3A1015-453RRR
- Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol*. 2021;19(1):55–71. doi:10.1038/s41579-020-0433-9
- Du L, Li Q, Yi H, Kuang T, Tang Y, Fan G. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus. *Biomed Pharmacother*. 2022;149:112839. doi:10.1016/j.biopha.2022.112839
- Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol*. 2016;16(6):341–352. doi:10.1038/nri.2016.42
- Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A comprehensive review of mechanisms and management. *Nutrients*. 2022;14(17):3525. doi:10.3390/nu14173525
- Chu Y, Sun S, Huang Y, et al. Metagenomic analysis revealed the potential role of gut microbiome in gout. *NPJ Biofilms Microb*. 2021;7(1):66. doi:10.1038/s41522-021-00235-2
- Wang Y, Wei J, Zhang W, et al. Gut dysbiosis in rheumatic diseases: a systematic review and meta-analysis of 92 observational studies. *EBioMed*. 2022;80:104055. doi:10.1016/j.ebiom.2022.104055
- Wrigley R, Phipps-Green AJ, Topless RK, et al. Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout. *Arthritis Res Ther*. 2020;22(1):45. doi:10.1186/s13075-020-2136-z
- Yu Y, Liu Q, Li H, Wen C, He Z. Alterations of the Gut microbiome associated with the treatment of hyperuricaemia in male rats. *Front Microbiol*. 2018;9:2233. doi:10.3389/fmicb.2018.02233
- Aron-Wisniewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. *Nat Rev Gastroenterol Hepatol*. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9
- Huang C, Shi G. Smoking and microbiome in oral, airway, gut and some systemic diseases. *J Transl Med*. 2019;17(1):225. doi:10.1186/s12967-019-1971-7
- Zhou X, Zhang B, Zhao X, et al. Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. *Food Funct*. 2021;12(12):5637–5649. doi:10.1039/D0FO03199B

27. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going. *Int J Epidemiol.* 2015;44(2):379–388. doi:10.1093/ije/dyv108
28. Inamo J. Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study. *Ann Rheum Dis.* 2021;80(7):e103. doi:10.1136/annrheumdis-2019-216565
29. Long Y, Tang L, Zhou Y, Zhao S, Zhu H. Causal relationship between gut microbiota and cancers: A two-sample Mendelian randomisation study. *BMC Med.* 2023;21(1):66. doi:10.1186/s12916-023-02761-6
30. Kurilshikov A, Medina-Gomez C, Bacigalupe R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. *Nat Genet.* 2021;53(2):156–165. doi:10.1038/s41588-020-00763-1
31. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol.* 2011;40(3):755–764. doi:10.1093/ije/dyr036
32. Curtin F, Schulz P. Multiple correlations and Bonferroni's correction. *Biol Psychiatry.* 1998;44(8):775–777. doi:10.1016/S0006-3223(98)00043-2
33. Lin S, Zhang T, Zhu L, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. *J Genet Genomics.* 2021;48(9):781–791. doi:10.1016/j.jgg.2021.06.009
34. Zhou D, Liu Y, Zhang X, et al. Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population. *Int J Mol Sci.* 2014;15(5):9149–9159. doi:10.3390/ijms15059149
35. Neogi T. Clinical practice. *Gout N Engl J Med.* 2011;364(5):443–452. doi:10.1056/NEJMc1001124
36. Stewart S, Rome K, Eason A, et al. Predictors of activity limitation in people with gout: a prospective study. *Clin Rheumatol.* 2018;37(8):2213–2219. doi:10.1007/s10067-018-4110-6
37. Wang Z, Li Y, Liao W, et al. Gut microbiota remodeling: a promising therapeutic strategy to confront hyperuricemia and gout. *Front Cell Infect Microbiol.* 2022;12:935723. doi:10.3389/fcimb.2022.935723
38. Guo Z, Zhang J, Wang Z, et al. Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. *Sci Rep.* 2016;6:20602. doi:10.1038/srep20602
39. Chiaro TR, Soto R, Zac Stephens W, et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. *Sci Transl Med.* 2017;9(380):eaaf9044. doi:10.1126/scitranslmed.aaf9044
40. Zhu L, Wu Q, Deng C, et al. Adaptive evolution to a high purine and fat diet of carnivores revealed by gut microbiomes and host genomes. *Environ Microbiol.* 2018;20(5):1711–1722. doi:10.1111/1462-2920.14096
41. Singh V, Yeoh BS, Walker RE, et al. Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation. *Gut.* 2019;68(10):1801–1812. doi:10.1136/gutjnl-2018-316250
42. Zhang YZ, Sui XL, Xu YP, Gu FJ, Zhang AS, Chen JH. NLRP3 inflammasome and lipid metabolism analysis based on UPLC-Q-TOF-MS in gouty nephropathy. *Int J Mol Med.* 2019;44(1):172–184. doi:10.3892/ijmm.2019.4176
43. Zhao J, Wei K, Jiang P, et al. Inflammatory response to regulated cell death in Gout and its functional implications. *Front Immunol.* 2022;13:888306. doi:10.3389/fimmu.2022.888306
44. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature.* 2009;461(7268):1282–1286. doi:10.1038/nature08530
45. Vasquez R, Oh JK, Song JH, Kang DK. Gut microbiome-produced metabolites in pigs: a review on their biological functions and the influence of probiotics. *J Anim Sci Technol.* 2022;64(4):671–695. doi:10.5187/jast.2022.e58
46. Wu YL, Zhang CH, Teng Y, et al. Propionate and butyrate attenuate macrophage pyroptosis and osteoclastogenesis induced by CoCrMo alloy particles. *Mil Med Res.* 2022;9(1):46. doi:10.1186/s40779-022-00404-0
47. Bian X, Wu W, Yang L, et al. Administration of Akkermansia muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. *Front Microbiol.* 2019;10:2259. doi:10.3389/fmicb.2019.02259
48. Dong L, Du H, Zhang M, et al. Anti-inflammatory effect of Rhein on ulcerative colitis via inhibiting PI3K/Akt/mTOR signaling pathway and regulating gut microbiota. *Phytother Res.* 2022;36(5):2081–2094. doi:10.1002/ptr.7429
49. Hosomi K, Saito M, Park J, et al. Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. *Nat Commun.* 2022;13(1):4477. doi:10.1038/s41467-022-32015-7
50. Sun B, Vatanen T, Jayasinghe TN, McKenzie E, Murphy R, O'Sullivan JM. Desacetyl- $\alpha$ -MSH and  $\alpha$ -MSH have sex specific interactions with diet to influence mouse gut morphology, metabolites and microbiota. *Sci Rep.* 2020;10(1):18957. doi:10.1038/s41598-020-75786-z
51. Yang Y, Dai D, Jin W, et al. Microbiota and metabolites alterations in proximal and distal gastric cancer patients. *J Transl Med.* 2022;20(1):439. doi:10.1186/s12967-022-03650-x
52. Miyagi Y, Higashiyama M, Gochi A, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. *PLoS One.* 2011;6(9):e24143. doi:10.1371/journal.pone.0024143
53. Yü TF, Adler M, Bobrow E, Gutman AB. Plasma and urinary amino acids in primary gout, with special reference to glutamine. *J Clin Invest.* 1969;48(5):885–894. doi:10.1172/JCI106047
54. Ishikawa T, Aw W, Kaneko K. Metabolic interactions of purine derivatives with human ABC Transporter ABCG2: Genetic testing to assess gout risk. *Pharmaceuticals.* 2013;6(11):1347–1360. doi:10.3390/ph6111347
55. Mahbub MH, Yamaguchi N, Takahashi H, et al. Alteration in plasma free amino acid levels and its association with gout. *Environ Health Prev Med.* 2017;22(1):7. doi:10.1186/s12199-017-0609-8
56. Tavella T, Rampelli S, Guidarelli G, et al. Elevated gut microbiome abundance of Christensenellaceae, Porphyromonadaceae and Rikenellaceae is associated with reduced visceral adipose tissue and healthier metabolic profile in Italian elderly. *Gut Microbes.* 2021;13(1):1–19. doi:10.1080/19490976.2021.1880221
57. Lin H, Meng L, Sun Z, et al. Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota. *Circ Heart Fail.* 2021;14(10):e008220. doi:10.1161/CIRCHEARTFAILURE.120.008220
58. Lan Y, Sun Q, Ma Z, et al. Seabuckthorn polysaccharide ameliorates high-fat diet-induced obesity by gut microbiota-SCFAs-liver axis. *Food Funct.* 2022;13(5):2925–2937. doi:10.1039/D1FO03147C
59. Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. *JAMA.* 2022;328(5):440–450. doi:10.1001/jama.2022.11390

60. Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ, Clardy J. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. *Proc Natl Acad Sci U S A*. 2019;116(26):12672–12677. doi:10.1073/pnas.1904099116
61. Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. *Ann Rheum Dis*. 2019;78(7):947–956. doi:10.1136/annrheumdis-2018-214856
62. Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. *Ann Rheum Dis*. 2017;76(9):1614–1622. doi:10.1136/annrheumdis-2016-211064
63. Yan H, Qin Q, Chen J, et al. Gut Microbiome Alterations in Patients With Visceral Obesity Based on Quantitative Computed Tomography. *Front Cell Infect Microbiol*. 2021;11:823262. doi:10.3389/fcimb.2021.823262
64. Ruuskanen MO, Erawijantari PP, Havulinna AS, et al. Gut Microbiome Composition Is Predictive of Incident Type 2 Diabetes in a Population Cohort of 5572 Finnish Adults. *Diabetes Care*. 2022;45(4):811–818. doi:10.2337/dc21-2358
65. Shao T, Shao L, Li H, Xie Z, He Z, Wen C. Combined Signature of the Fecal Microbiome and Metabolome in Patients with Gout. *Front Microbiol*. 2017;8:268. doi:10.3389/fmicb.2017.00268
66. Wang M, Fan J, Huang Z, Zhou D, Wang X. Causal relationship between Gut microbiota and Gout: A Two-sample Mendelian randomization study. *Nutrients*. 2023;15(19):4260. doi:10.3390/nu15194260
67. Lou Y, Liu B, Jiang Z, et al. Assessing the causal relationships of gut microbial genera with hyperuricemia and gout using two-sample Mendelian randomization. *Nutr Metab Cardiovasc Dis*. 2024;34(4):1028–1035. doi:10.1016/j.numecd.2024.01.021
68. Hou T, Dai H, Wang Q, et al. Dissecting the causal effect between gut microbiota, DHA, and urate metabolism: a large-scale bidirectional Mendelian randomization. *Front Immunol*. 2023;14:1148591. doi:10.3389/fimmu.2023.1148591

## Orthopedic Research and Reviews

Dovepress

### Publish your work in this journal

Orthopedic Research and Reviews is an international, peer-reviewed, open access journal that focusing on the patho-physiology of the musculoskeletal system, trauma, surgery and other corrective interventions to restore mobility and function. Advances in new technologies, materials, techniques and pharmacological agents are particularly welcome. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/orthopedic-research-and-reviews-journal>